Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Erich Fisher, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by David Fisher and Arlene Sharpe.
Connection Strength

0.364
  1. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.243
  2. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 07 27; 547(7664):413-418.
    View in: PubMed
    Score: 0.047
  3. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.038
  4. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013 Oct 01; 2(10):e26615.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.